Antares Pharma Long Term Debt

Antares Pharma (ATRS) currently reports a long-term debt of $18M as of March 2022. That compares with $15M in the prior-year period — up 21.2% year over year. Use the charts on this page to explore Antares Pharma's long-term debt history and peer comparisons.

Antares Pharma's long-term debt increased from $15M to $18M — a 21.2% year-over-year increase (period ending March 2022). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Antares Pharma reported $18M in long-term debt as of March 2022. That compares with $15M in the prior-year period — up 21.2% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current long-term debt of $18M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Antares Pharma, and consider following ATRS for alerts when major investors trade the stock.

Antares Pharma is classified in the Healthcare sector. On long-term debt, it currently shows $18M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing ATRS with unrelated industries.